EarningsQ2 2026 Earnings Report
MX:KYNB Q2 2026 EPS Results
Actual EPS$53.56
Consensus EPS-$57.62
Beat/MissBeat by +$111.18
One Year Ago EPS-$34.02
MX:KYNB Q2 2026 Revenue Results
Actual Revenue-$26.67M
Expected Revenue$37.82M
Beat/MissMissed by -$64.49M
YoY Revenue Growth-209.35%
Earnings Announcement Details
QuarterQ2 2026
Date08/13/2026
TimeAfter Close
Conference CallThursday, August 13, 2026
MX:KYNB Upcoming Earnings
Kyntra Bio's next earnings date is estimated for November 9, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:KYNB Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple meaningful clinical and operational positives: concrete Phase I/IST efficacy signals for FG-3246 (with a clear plan for a Phase II interim readout in Q4 2026), a finalized Phase III protocol and compelling subgroup data for roxadustat, a unique non-PSMA therapeutic + companion diagnostic position, and a positive swing to net income with a cash runway into 2028. Offsetting these were notable near-term financial headwinds (negative reported revenue and higher operating expenses), safety and biomarker confirmation risks that require larger data sets, enrollment and market dynamics uncertainty (Pluvicto adoption) and the dependence on partnering/capital for a registrational path for roxadustat. On balance, the highlights modestly outweigh the lowlights due to actionable clinical progress and a forthcoming near-term catalyst (FG-3246 interim) alongside sufficient cash runway to advance programs.Company Guidance
Promising FG-3246 Early Clinical Activity
Phase I monotherapy: median rPFS 8.7 months, PSA50 response 36%, ORR 20% (in 25 RECIST-evaluable patients) with a meaningful median duration of response of 7.5 months; investigator-initiated study (FG-3246 + enzalutamide) showed median rPFS of 7.0 months overall and 10.1 months in patients with only one prior ARPI (PSA50 40%).
Biomarker-Linked Companion Imaging (FG-3180)
FG-3180 PET imaging showed a trend where higher tumor uptake (higher SUV normalized to blood pool) was associated with greater PSA50 response to FG-3246, providing first observed association between CD46 expression and response and supporting a potential patient-selection biomarker strategy.
Robust Phase II Design and Near-Term Catalyst
Phase II monotherapy trial enrolling 75 patients (post-one ARPI, pre-chemo) across three dose levels (1.8, 2.4, 2.7 mg/kg) with primary objective to select optimal phase III dose; interim analysis of 36 patients on track for Q4 2026 (endpoints: PSA50, ORR, safety, PK, exposure-response).
Safety Strategy to Improve Tolerability
Use of primary prophylactic G-CSF (adopted after IST) led to a significant decrease in Grade ≥3 neutropenia versus phase I monotherapy, and is built into the Phase II design to reduce dose interruptions and maintain exposure.
Differentiated Non-PSMA Positioning
Kyntra is the only non-PSMA mid/late-stage program combining a therapeutic ADC (FG-3246) with a companion PET imaging agent (FG-3180), targeting CD46 which is estimated to be highly expressed in ~50%–70% of mCRPC and more uniform vs PSMA — a potentially differentiated commercial and clinical niche.
Roxadustat Phase III Readiness and Positive MATTERHORN Subgroup
Phase III protocol finalized with primary endpoint of 8-week transfusion independence over first 24 weeks; plan to initiate registrational trial in Q4 2026. Post hoc MATTERHORN high-transfusion-burden subgroup: 36% on roxadustat achieved ≥8 weeks transfusion independence vs 7% placebo (nominal P=0.041).
Financial Turnaround and Cash Runway
Reported net income from continuing operations of $12.0M ($2.96 per basic & diluted share) in Q2 2026 versus a net loss of $13.7M ($3.38 loss per share) in Q2 2025. Company holds $95.7M in cash equivalents, investments and receivables and expects cash runway into 2028.
MX:KYNB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed